STAT3 and cancer: Additionally, several ongoing clinical trials are evaluating STAT3 inhibitors in cancer treatment, including VVD-130850 (ClinicalTrials.gov NCT06188208) for advanced solid and hematologic malignancies, silibinin (NCT05689619) for preventing brain metastases in non–small cell lung cancer and breast cancer, WP1066 (NCT05879250) in combination with radiotherapy for glioblastoma, and danvatirsen (NCT05986240) in combination with venetoclax for high-risk myelodysplastic syndrome and acute myeloid leukemia.